Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Growth Hormone Deficiency

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    103 result(s) found for: Growth Hormone Deficiency. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2005-005593-79 Sponsor Protocol Number: A6391004 Start Date*: 2006-06-02
    Sponsor Name:Pfizer Limited
    Full Title: A Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency
    Medical condition: Paediatric Growth Hormone Deficiency
    Disease: Version SOC Term Classification Code Term Level
    8.1 10056438 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000290-39 Sponsor Protocol Number: NN8640-4043 Start Date*: 2014-11-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: A multicentre, multinational, randomised, open-labelled, parallel-group, active-controlled trial to compare the safety of once weekly dosing of NNC0195-0092 with daily Norditropin® FlexPro® for 26 ...
    Medical condition: Growth hormone deficiency in adults
    Disease: Version SOC Term Classification Code Term Level
    17.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019296-30 Sponsor Protocol Number: Start Date*: 2010-05-18
    Sponsor Name:University Hospital Birmingham NHS Foundation Trust
    Full Title: A pharmacokinetic and pharmacodynamic study of recombinant human IGF-I (rhIGF-I) in three boys with ALS deficiency, and insulin sensitivity and bone density in patients and heterozygous first-degre...
    Medical condition: ALS (acid label subunit) deficiency
    Disease: Version SOC Term Classification Code Term Level
    12.1 10056438 Growth Hormone Deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000013-20 Sponsor Protocol Number: NN8640-4042 Start Date*: 2013-12-09
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, open-labelled, active-controlled, multinational, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of long-acting growth...
    Medical condition: Growth hormone deficiency in children
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SI (Completed) BE (Completed) AT (Completed) SE (Completed) ES (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-001695-34 Sponsor Protocol Number: LUM-201-04 Start Date*: 2022-09-08
    Sponsor Name:Lumos Pharma, Inc.
    Full Title: An Open-Label, Multicenter, Phase 2 Study to Evaluate Growth and Safety of LUM-201 Following 12 Months of Daily rhGH Treatment in Children with Idiopathic Growth Hormone Deficiency who have Previou...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002892-16 Sponsor Protocol Number: NN8640-4054 Start Date*: 2014-10-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: A multicentre, multinational, randomised, parallel-group, placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-00...
    Medical condition: Growth hormone deficiency in adults
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2014-004525-41 Sponsor Protocol Number: 14VR4 Start Date*: 2015-04-10
    Sponsor Name:Versartis, Inc.
    Full Title: Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children w...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) NL (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001674-32 Sponsor Protocol Number: NordiNet-IOS Start Date*: 2009-04-29
    Sponsor Name:Novo Nordisk Farma Oy
    Full Title: NordiNet International Outcome Study (NordiNet IOS)
    Medical condition: Small Gestation Age, Turner Syndrome, Growth Hormone Deficiency
    Disease: Version SOC Term Classification Code Term Level
    16.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2007-003586-41 Sponsor Protocol Number: A6281289 Start Date*: 2007-12-17
    Sponsor Name:Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
    Full Title: Placebo-controlled trial on the efficacy of growth hormone replacement therapy in patients with growth hormone deficiency after traumatic brain injury
    Medical condition: Growth hormone deficiency after traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056438 Growth hormone deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) SE (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-008240-25 Sponsor Protocol Number: NN8630-1824 Start Date*: 2009-09-02
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, open-labelled, single dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of pegylated long-acting human growth hormone (NNC126-0083)...
    Medical condition: growth hormone deficiency (GHD) in children
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056438 Growth hormone deficiency LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) SI (Completed) GB (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-004580-39 Sponsor Protocol Number: TOSCA_GHDDP Start Date*: 2018-07-18
    Sponsor Name:AOU FEDERICO II
    Full Title: Treatment of Growth Hormone Deficiency associated with Chronic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Study
    Medical condition: Growth Hormone Deficiency associated with Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005587-82 Sponsor Protocol Number: A6391003 Start Date*: 2006-06-12
    Sponsor Name: [...]
    1.
    2. Pfizer AB
    3. Pfizer Ltd
    Full Title: A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients
    Medical condition: Adult Growth Hormone Deficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056438 Growth hormone deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) DK (Completed) BE (Completed) GB (Completed) NL (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) PL (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000384-26 Sponsor Protocol Number: BPLG-005 Start Date*: 2005-11-10
    Sponsor Name:LG Life Science Ltd. [...]
    1. LG Life Science Ltd.
    2. BioPartners
    Full Title: A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency.
    Medical condition: growth hormone deficiency in adults
    Disease: Version SOC Term Classification Code Term Level
    8.0 10056438 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Ongoing) SE (Completed) CZ (Completed) GB (Completed) SK (Completed) FR (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-005054-31 Sponsor Protocol Number: 24531 Start Date*: 2005-07-15
    Sponsor Name:Serono International S.A.
    Full Title: A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome prepubertal children treated with Saizen
    Medical condition: - growth failure in children caused by decreased or absent secretion of endogenous growth hormone. - growth failure in girls with gonadal dysgenesis (Turner Syndrome), confirmed by chromosomal anal...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10056438 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) ES (Completed) DE (Completed) AT (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002736-13 Sponsor Protocol Number: TV1106-IMM-30022 Start Date*: 2015-08-19
    Sponsor Name:Teva Pharmaceutical Industries Ltd.
    Full Title: A phase 3, multicenter, randomized, open-label, comparator-controlled study to assess safety and tolerability of weekly TV-1106 compared to daily rhGH (Genotropin®) in adults with growth hormone-de...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Completed) SE (Prematurely Ended) IT (Prematurely Ended) AT (Completed) ES (Prematurely Ended) SI (Prematurely Ended) LT (Prematurely Ended) GR (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004313-39 Sponsor Protocol Number: TCH-306EXT Start Date*: 2022-06-17
    Sponsor Name:Ascendis Pharma Endocrinology Division A/S
    Full Title: A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults with Growth Hormone Deficiency
    Medical condition: Adult Growth Hormone Deficiency (AGHD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) SK (Completed) FR (Completed) ES (Ongoing) DE (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000446-56 Sponsor Protocol Number: CRT076 Start Date*: 2016-03-07
    Sponsor Name:Cristália Produtos Químicos Farmacêuticos Ltda.
    Full Title: Clinical study to compare recombinant human growth hormone Cristalia (r-hGH Cristalia) versus Genotropin® in prepubertal children with growth deficiency due to deficiency of growth hormone.
    Medical condition: Growth deficiency due to growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    18.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2012-004975-37 Sponsor Protocol Number: TV1106-GHD-201 Start Date*: 2013-01-21
    Sponsor Name:Teva Pharmaceutical Industries Ltd.
    Full Title: A 64-Week (12-week core phase and 52-week safety extension), Phase II, Multicenter, Randomized, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults with G...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) GR (Completed) SI (Completed) DE (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004835-72 Sponsor Protocol Number: UB-MedSci-001/2004 Start Date*: 2005-01-12
    Sponsor Name:University of Birmingham [...]
    1. University of Birmingham
    2. University Hospital Birmingham Foundation NHS Trust
    Full Title: A study to determine the effects of growth hormone (GH) replacement therapy on quality of life and cardiovascualr risk in GH deficient adults
    Medical condition: Growth hormone deficiency in adult life
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001061-29 Sponsor Protocol Number: NN8630-1823 Start Date*: 2008-06-17
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, double blind, placebo-controlled, multiple dose, dose-escalating, sequential dose group trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of pegylated lo...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056438 Growth hormone deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 08:35:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA